Jaguar Health (NASDAQ:JAGX – Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, November 14th. Investors interested in participating in the company’s conference call can do so using this link.
Jaguar Health (NASDAQ:JAGX – Get Free Report) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter. Jaguar Health had a negative net margin of 402.00% and a negative return on equity of 1,146.88%. The company had revenue of $2.68 million for the quarter. On average, analysts expect Jaguar Health to post $-6 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Jaguar Health Price Performance
Shares of Jaguar Health stock opened at $0.29 on Friday. Jaguar Health has a 1 year low of $0.21 and a 1 year high of $11.99. The company has a current ratio of 0.97, a quick ratio of 0.69 and a debt-to-equity ratio of 2.89. The company has a 50 day simple moving average of $0.30 and a two-hundred day simple moving average of $0.49.
Wall Street Analyst Weigh In
Institutional Investors Weigh In On Jaguar Health
Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in shares of Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 141,796 shares in the last quarter. Citigroup Inc. purchased a new position in shares of Jaguar Health during the first quarter worth approximately $34,000. Renaissance Technologies LLC purchased a new position in shares of Jaguar Health during the first quarter worth approximately $1,079,000. Goldman Sachs Group Inc. raised its stake in shares of Jaguar Health by 153.3% during the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 33,148 shares in the last quarter. Finally, Virtu Financial LLC raised its stake in shares of Jaguar Health by 76.1% during the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 99,073 shares in the last quarter. 12.24% of the stock is currently owned by institutional investors.
About Jaguar Health
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Five stocks we like better than Jaguar Health
- Basic Materials Stocks Investing
- MarketBeat Week in Review – 11/6 – 11/10
- What Are Dividend Contenders? Investing in Dividend Contenders
- Data giants MongoDB and Snowflake just got upgraded
- How to Invest in the Healthcare Sector
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.